e-learning
resources
Copenhagen 2005
Sunday 18.09.2005
Interstitial lung diseases and sarcoidosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Serum type III procollagen peptide in idiopathic pulmonary fibrosis: peptide levels and anti-fibrosis therapy
M. Bando, S. Ohno, Y. Sugiyama (Kawachi, Japan)
Source:
Annual Congress 2005 - Interstitial lung diseases and sarcoidosis
Session:
Interstitial lung diseases and sarcoidosis
Session type:
Poster Discussion
Number:
316
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Bando, S. Ohno, Y. Sugiyama (Kawachi, Japan). Serum type III procollagen peptide in idiopathic pulmonary fibrosis: peptide levels and anti-fibrosis therapy. Eur Respir J 2005; 26: Suppl. 49, 316
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Related content which might interest you:
Serum levels of a MMP-12 generated type IV collagen fragment is elevated in COPD and IPF patients
Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases
Year: 2013
Oral immunotherapy with type V collagen in idiopathic pulmonary fibrosis
Source: Eur Respir J 2015; 45: 1393-1402
Year: 2015
Type XIX collagen quantified in serum targeting the anti-tumorigenic NC1 domain is elevated in early and late stage lung carcinoma patients and COPD
Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer
Year: 2020
Serum surfactant protein D predicts the outcome of patients with idiopathic pulmonary fibrosis treated with pirfenidone
Source: International Congress 2017 – IPF: from the bench to the bedside
Year: 2017
Nintedanib and pirfenidone inhibit collagen synthesis and maturation at several regulatory levels
Source: International Congress 2016 – ILD pathogenesis
Year: 2016
Prognostic value of serum N-terminal brain natriuretic peptide type B for pulmonary hypertension among patients with usual interstitial pneumonia and sarcoidosis
Source: Annual Congress 2007 - Pulmonary vascular involvement in smoking and respiratory diseases
Year: 2007
C-reactive protein and the type IV collagen measurementin severe COPD: Value of roflumilast
Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science
Year: 2021
Serum and EBC levels of cross-linked carboxy-terminal telopeptide of type I collagen in young patients with non-CF bronchiectases
Source: Annual Congress 2009 - Mechanisms of lung injury: COPD, asthma and acute lung injury
Year: 2009
Increased mRNA expression of collagen V gene in pulmonary fibrosis of systemic sclerosis
Source: Annual Congress 2009 - Bronchoalveolar lavage and phenotyping in diffuse parenchymal lung disease
Year: 2009
The effects of angiotensin II and related peptides on intracellular Ca2+ release in human lung fibroblasts
Source: Annual Congress 2013 –The role of hormones and cytokines in lung injury
Year: 2013
Type V collagen nasal tolerance regulates collagen mRNA synthesis in pulmonary remodeling of experimental systemic sclerosis
Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders
Year: 2008
Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression
Source: Eur Respir J 2014; 43: 1430-1438
Year: 2014
Serum surfactant protein D may predict the effect of pirfenidone in idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013
Collagen degradation profile in serum of patients with COPD or IPF
Source: Annual Congress 2012 - Monitoring of airway diseases: far from the airways
Year: 2012
A neo-epitope of collagen type VII (C7) is elevated in serum of patients with COPD and SSC
Source: International Congress 2016 – Exploring mechanisms in health and disease
Year: 2016
Polymorphisms in the type IV collagen alpha3 gene and the risk of COPD
Source: Eur Respir J 2008; 32: 35-41
Year: 2008
A novel serum biomarker of type XXVIII collagen turnover is elevated in lung cancer but not in COPD
Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer
Year: 2020
C21, a nonpeptide angiotensin II type 2 receptor agonist attenuates lung fibrosis and associated cardiac dysfunction
Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease
Year: 2015
NHLRC2 mRNA and protein expression in idiopathic pulmonary fibrosis
Source: Virtual Congress 2021 – Translational and other aspects of idiopathic interstitial pneumonia
Year: 2021
Plasma levels of circulating cell-free DNA are increased in idiopathic pulmonary fibrosis but do not correlate with disease severity
Source: International Congress 2019 – Biomarkers of idiopathic interstitial pneumonia
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept